William Lis
Director/Board Member at ZAI LAB LIMITED
Net worth: 701 976 $ as of 2024-04-29
Profile
William Lis is currently the Executive Chairman & Chief Executive Officer at Jasper Tx Corp., the Chief Executive Officer at Tr1x, Inc., and an Independent Director at Zai Lab Ltd.
Previously, he served as the Chief Executive Officer & Director at Portola Pharmaceuticals LLC from 2012 to 2018.
He was also the Non-Executive Chairman at Jasper Therapeutics, Inc. from 2022 to 2023.
Additionally, he worked as a Product Director at COR Therapeutics, Inc. from 1999 to 2002 and as a Marketing Director at Millennium Pharmaceuticals, Inc. in 2003.
He held the position of Senior Director-Business Development at Portola Pharmaceuticals LLC in 2005.
He has also served as a Director at the Biotechnology Innovation Organization.
From 2018 to 2021, he was an Independent Director at Eidos Therapeutics, Inc. Prior to that, he was the Vice President-Business Development at Scios, Inc. from 2007 to 2008 and a Principal at Ethicon Endo-Surgery, Inc. He obtained his undergraduate degree from the University of Maryland.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ZAI LAB LTD.
0.04% | 2023-06-29 | 422,330 ( 0.04% ) | 701 976 $ | 2024-04-29 |
William Lis active positions
| Companies | Position | Start |
|---|---|---|
| ZAI LAB LIMITED | Director/Board Member | 2018-09-30 |
Jasper Tx Corp.
 Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | Chief Executive Officer | 2019-11-30 |
Tr1x, Inc.
 Tr1x, Inc. Miscellaneous Commercial ServicesCommercial Services Tr1x, Inc. is an American biotechnology company. The company was founded by Jan Egbert de Vries. Jan Egbert de Vries has been the CEO since incorporation. | Chief Executive Officer | 2024-01-16 |
Former positions of William Lis
| Companies | Position | End |
|---|---|---|
| EIDOS THERAPEUTICS, INC. | Director/Board Member | 2021-01-25 |
| PORTOLA PHARMACEUTICALS, INC. | Chief Executive Officer | 2018-07-31 |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Corporate Officer/Principal | 2008-03-31 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2005-07-31 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Sales & Marketing | - |
Training of William Lis
| University of Maryland | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ZAI LAB LIMITED | Health Technology |
| JASPER THERAPEUTICS, INC. | Finance |
| Private companies | 9 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Ethicon Endo-Surgery, Inc.
 Ethicon Endo-Surgery, Inc. Medical SpecialtiesHealth Technology Ethicon Endo-Surgery, Inc. manufactures surgical devices and equipments. Its products include the ENDOPATH XCEL access system, CONTOUR curved cutter stapler, HARMONIC ultrasonic cutting and coagulation surgical devices and the MAMMOTOME breast biopsy system. The company was founded in 1992 and is headquartered in Cincinnati, OH. | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Jasper Tx Corp.
Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | Health Technology |
Tr1x, Inc.
Tr1x, Inc. Miscellaneous Commercial ServicesCommercial Services Tr1x, Inc. is an American biotechnology company. The company was founded by Jan Egbert de Vries. Jan Egbert de Vries has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- William Lis
